Markets:

Overview

News

Currencies

International

Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

2.780 -0.020 (-0.71%)

Streaming Delayed Price Updated: 1:06 PM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

August 09, 2025

From Pomerantz LLP

Via GlobeNewswire

Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT

August 08, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT

August 08, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

August 07, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Levi & Korsinsky Notifies Shareholders of Altimmune, Inc. (ALT) of a Class Action Lawsuit and an Upcoming Deadline

August 07, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Levi & Korsinsky Notifies Shareholders of Altimmune, Inc. (ALT) of a Class Action Lawsuit and an Upcoming Deadline

August 07, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Investor Alert: Robbins LLP Informs Investors of the Altimmune, Inc. Class Action Lawsuit

August 06, 2025

From Robbins LLP

Via GlobeNewswire

ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm

August 06, 2025

From The Schall Law Firm

Via Business Wire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

August 06, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

August 05, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

August 01, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

July 28, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

July 23, 2025

From Pomerantz LLP

Via GlobeNewswire

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm

July 19, 2025

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

July 18, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT

July 14, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

July 10, 2025

From Pomerantz LLP

Via GlobeNewswire

Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

July 10, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

July 03, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

July 01, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

June 30, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

June 28, 2025

From Pomerantz LLP

Via GlobeNewswire

Benzinga Bulls And Bears: Nvidia, Micron, HIMS — And Markets Soar On Mideast And Tariff Relief ↗

June 28, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts ↗

June 27, 2025

Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight loss at 24 weeks.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

June 26, 2025

Via ACCESS Newswire

Top movers in Thursday's session ↗

June 26, 2025

Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 26, 2025

Via Benzinga

Crude Oil Gains Over 1%; Walgreens Posts Upbeat Earnings ↗

June 26, 2025

Via Benzinga

Here are the top movers in Thursday's session. ↗

June 26, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Gapping stocks in Thursday's session ↗

June 26, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Altimmune, Inc. - Common Stock (NQ:ALT)

All News about Altimmune, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today